<DOC>
	<DOCNO>NCT00726544</DOCNO>
	<brief_summary>The purpose ascending-dose research study determine whether administration ARC1779 Injection improve subject 's health profile protect brain , heart , kidney damage due formation small blood clot blood vessel . It also determine safety ARC1779 Injection , ARC1779 Injection enter leave blood tissue time , effect laboratory test relate blood clotting , heart brain function , body system .</brief_summary>
	<brief_title>Clinical Outcome Study ARC1779 Injection Patients With Thrombotic Microangiopathy</brief_title>
	<detailed_description />
	<mesh_term>Purpura , Thrombocytopenic</mesh_term>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Purpura , Thrombotic Thrombocytopenic</mesh_term>
	<mesh_term>Thrombotic Microangiopathies</mesh_term>
	<criteria>Male female ; ≥18 ≤75 year age ; Diagnosis TMA base presence : Thrombocytopenia , define platelet count &lt; 100 x 109 per liter ; Microangiopathic hemolytic anemia , define negative finding direct antiglobulin test , evidence accelerate red blood cell ( RBC ) production destruction ) ; AND Absence clinically apparent alternative explanation thrombocytopenia anemia , e.g. , disseminate intravascular coagulation ( DIC ) , eclampsia , HELLP syndrome , Evans syndrome ; Females : nonpregnant commit use effective , redundant method contraception ( i.e. , self male partner ) throughout study least 30 day discontinuation study drug treatment ; Males : commit use medically acceptable contraceptive ( abstinence use condom spermicide ) throughout study least 30 day discontinuation study drug treatment ; Not receive unlicensed investigational agent ( drug , device , bloodderived product ) within 30 day prior randomization , may receive investigational agent 30 day postrandomization ( note : investigational use treatment TMA license immunomodulator , e.g. , rituximab , permit time relative randomization ) ; Capable understand comply protocol , he/she ( legal representative ) must sign informed consent document prior performance studyrelated procedure . Patients become acutely ill follow recent treatment achievement brief remission acute TMA may enrol study ALL following condition meet : Disease activity patient unabated ( e.g . persistent thrombocytopenia microangiopathic hemolytic anemia ongoing neurological symptom and/or troponin elevation ) ; The last plasma exchange patient 's preceding course treatment occur least 7 day prior ; The patient undergo splenectomy precede course treatment ; The new course plasma exchange ongoing 3 day . Females : pregnant &lt; 24 hour postpartum , breastfeed ; History bleed diathesis evidence active abnormal bleeding within previous 30 day ; Disseminated malignancy comorbid illness limit life expectancy ≤3 month independent TMA disorder . Diagnosis TMA account finding thrombocytopenia hemolytic anemia ( e.g. , DIC , HELLP syndrome , Evans syndrome ) ; Diagnosis DIC verify laboratory value Ddimer , fibrinogen , prothrombin time ( PT ) , activate partial thromboplastin time ( aPTT ) . Patients become acutely ill follow recent treatment achievement brief remission acute TMA may enrol study ANY follow condition meet : The last plasma exchange patient 's preceding course treatment occur less 7 day prior ; The patient underwent splenectomy precede course treatment ; The new course plasma exchange ongoing 3 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>thrombocytopenia</keyword>
	<keyword>microangiopathic hemolytic anemia</keyword>
	<keyword>von Willebrand Factor</keyword>
	<keyword>ADAMTS13</keyword>
</DOC>